MergerMay 15, 2026, 04:12 PM
VYNE Therapeutics to Merge with Yarrow Bioscience; Q1 Net Loss $3.6M
AI Summary
VYNE Therapeutics Inc. announced a proposed merger with Yarrow Bioscience, Inc., a clinical-stage biotechnology company, expected to close in Q3 2026. This follows a strategic review and the termination of clinical trials for its lead product candidates, VYN202 and repibresib, due to a clinical hold and failure to meet primary endpoints, respectively. For Q1 2026, the company reported a net loss of $3.6 million, a significant improvement from $8.6 million in Q1 2025, largely due to reduced R&D expenses as it winds down operations.
Key Highlights
- Entered merger agreement with Yarrow Bioscience, Inc. in December 2025, expected to close Q3 2026.
- Yarrow Bioscience secured $100.0 million in Series A financing and $100.0 million in pre-closing financing.
- Q1 2026 net loss was $3.6 million, compared to $8.6 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $24.9 million as of March 31, 2026.
- Research and development expenses decreased to $0.8 million in Q1 2026 from $6.1 million in Q1 2025.
- Terminated Phase 1b trial for VYN202 and Phase 2b trial for repibresib due to clinical hold and failed endpoint.
- Expects to declare a special cash dividend of $14.5 million to $16.5 million prior to merger closing.
Price Impact
More from VYNE